NCT06857305View on ClinicalTrials.gov

Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

July 13, 2026

Study Completion Date

July 13, 2026

Conditions
Breast Cancer Metastatic
Interventions
DRUG

Eribulin biweekly regimen

Eribulin biweekly regimen

DRUG

Eribulin standard regimen

Eribulin standard regimen

Trial Locations (1)

100020

Cancer Hospital Chinses Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Ma Fei，MD

OTHER